Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15873672 | 0.96 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL15863260 | 0.96 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL3516295 | 0.95 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL28172547 | 0.84 | SLC6A2 (0.49) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL28029020 | 0.83 | SLC6A2 (0.50) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19772416 | 0.82 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL19767368 | 0.82 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL17452485 | 0.82 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL19772413 | 0.82 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2CCR2 | |
| SCHEMBL3522688 | 0.81 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| US-5047432-A | Antidepressants | THE BOOTS COMPANY PLC (GB) | 1991-09-10 | — | — | US | disclosed |
| US-4925879-A | ANTIDEPRESSANTS | BOOTS COMPANY, PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0191542-B1 | ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES | The Boots Company PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 467/4885SLC6A3 553/4885SLC6A2 1157/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 511/4885SLC6A3 717/4885SLC6A2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.